NEW YORK (GenomeWeb News) – Epizyme today said that Abbott will develop a molecular companion diagnostic test for a leukemia drug candidate that the Cambridge, Mass.-based firm is developing.
Abbott will develop a test based on its fluorescence in situ hybridization technology to detect genetic alterations of mixed lineage leukemia, an aggressive subtype of acute myeloid leukemia and acute lymphoblastic leukemia.
Epizyme is developing an inhibitor targeting the DOT1L histone methyltransferase for the treatment of mixed lineage leukemia and will use the Abbott test to detect MLL genetic alterations that lead to the oncogenic function of DOT1L.
Further terms of the alliance were not disclosed.